Last reviewed · How we verify
NCT04519476
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Status unknown
Phase 1
Last updated 31 October 2023
What this trial tests
Phase 1 trial testing Selinexor in Refractory Multiple Myeloma in 22 participants. Status unknown.
Timeline
1 November 2020
Primary endpoint
29 December 2023
29 December 2023
29 December 2023
Quick facts
| Lead sponsor | Oncotherapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 1 November 2020 |
| Primary completion | 29 December 2023 |
| Estimated completion | 29 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Selinexor — full drug profile →
- Lenalidomide — full drug profile →
- Methylprednisolone (methylprednisolone) — full drug profile →
Conditions studied
- Refractory Multiple Myeloma — all drugs for Refractory Multiple Myeloma →
Sponsor
Oncotherapeutics — full company profile →
Who can join
18 and older, any sex, with Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Selinexor: Targeting a novel pathway in multiple myeloma.
Mo CC, Yee AJ, Midha S, Hartley-Brown MA, et al · · 2023 · cited 20× · PMID 37601856 · DOI 10.1002/jha2.709 -
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
McCurdy A, Visram A. · · 2022 · cited 8× · PMID 36417082 · DOI 10.1007/s11899-022-00682-4 -
Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
Neupane K, Wahab A, Masood A, Faraz T, et al · · 2021 · cited 7× · PMID 34234609 · DOI 10.2147/jbm.s317966 -
Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.
Aumann WK, Kazi R, Harrington AM, Wechsler DS. · · 2024 · cited 3× · PMID 39161560 · DOI 10.3389/or.2024.1427497 -
Modulation of anti-tumour immunity by XPO1 inhibitors.
Fisher JG, Bartlett LG, Kashyap T, Walker CJ, et al · · 2025 · cited 2× · PMID 40291981 · DOI 10.37349/etat.2025.1002310 -
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
Sokolova V, Gruber R, Pammer LM, Kocher F, et al · · 2024 · cited 1× · PMID 39729162 · DOI 10.1007/s11033-024-10169-5
Verify or expand the search:
- PubMed search for NCT04519476
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Selinexor
Trials testing the same drug.
- NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · Phase 2 · not yet recruiting
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07204041 — Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory · Phase 2 · active not recruiting
- NCT06966154 — A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se · Phase 1, PHASE2 · recruiting
- NCT06900088 — Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients · Phase 2 · not yet recruiting
Other recruiting trials for Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07181941 — Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refrac · Phase 1, PHASE2 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07093554 — Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patie · Phase 1 · recruiting
- NCT07045727 — Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Olde · NA · recruiting
- NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
Other Oncotherapeutics trials
Trials by the same sponsor.
- NCT06225310 — A Trial of Selinexor, Ruxolitinib and Methylprednisolone · Phase 1 · recruiting
- NCT06115135 — A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT03733691 — Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients · Phase 2 · terminated
- NCT03104270 — Combination Study for High Risk Multiple Myeloma Patients · Phase 2 · terminated
- NCT02188368 — Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04519476 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oncotherapeutics
- Last refreshed: 31 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04519476.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing